Below is Validea's guru fundamental report for SYNOPSYS INC (SNPS). Of the 22 guru strategies we follow, SNPS rates highest using our Twin Momentum Investor model based on the published strategy of ...
If the concept of personalized medicine is to be realized, it is increasingly clear that single nucleotide polymorphisms (SNPs), the most common genetic variations between human beings, will be a key ...
Synopsys, Inc. SNPS shares have appreciated 8.2% year to date, outperforming the Zacks Computer - Software industry’s decline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results